JC Hofmann, MD 1,2 ; KM Grant, MD 3 ; DD Kiprov, MD 1,2. Apheresis Care Group, 2. Division of Immunotherapy, 3
|
|
- Frederick Webster
- 6 years ago
- Views:
Transcription
1 Greater Than Ninety Percent of Patients with Acute Leukemia and Hyperleukocytosis Who Receive Leukocytapheresis Treatment Successfully Undergo Induction Chemotherapy: Follow-up Analysis of Data from JC Hofmann, MD 1,2 ; KM Grant, MD 3 ; DD Kiprov, MD 1,2 1 Apheresis Care Group, 2 Division of Immunotherapy, 3 Division of Hematology, Department of Medicine, California Pacific Medical Center, San Francisco, California 1
2 Disclosure of Conflicts of Interest Greater Than Ninety Percent of Patients with Acute Leukemia and Hyperleukocytosis Who Receive Leukocytapheresis Treatment Successfully Undergo Induction Chemotherapy Jan Hofmann, MD has reported the following financial relationships with commercial interests related to the content of this educational activity: Consulting Fees: Fresenius Medical Care 2
3 Hematologic Diseases (ASFA 2013 Categories) Disease Category Rec. Grade Primary, idiopathic TTP I 1A Thrombotic microangiopathy (TMA): - Ticlopidine I 1B - Clopidogrel III 2B - Cyclosporine/Tacrolimus III 2C - Gemcitabine IV 2C - HSCT-associated (refractory) III 1B Hyperviscosity (monoclonal gammopathies) I 1B Catastrophic Antiphospholipid Syndrome (CAPS) II 2C Hyperleukocytosis: - Leukostasis (WBC depletion) I 1B - Prophylaxis (AML; ALL, if WBC>400K) III 2C Sickle cell disease: - acute CVA (RBCX) I 1C - acute chest syndrome (RBCX) II 1C Malaria (severe falciparum malaria; RBCX) II 2B 3
4 Acute Leukemia (with hyperleukocytosis): Hyperleukocytosis: Circulating WBC or leukemic blast cell count >100 X 10 9 /L (>100K) Acute Myelogenous Leukemia (AML): very large, stiff myeloblasts Acute Lymphoblastic Leukemia (ALL): lg., deformable lymphoblasts Leukostasis (clinical presentation): hyperviscosity, microvascular leukoaggregates, tissue ischemia, infarction/thrombosis, hemorrhage: CNS symptoms (confusion, somnolence, delirium, coma, hemorrhage) Pulmonary complications (dyspnea, hypoxemia, respiratory failure, diffuse alveolar hemorrhage, pulmonary infiltrates). AML myeloblasts ( endothelial adhesion molecule expression) AML (WBC >100K; occas. >50K); ALL (WBC >400K) 4
5 Acute Leukemia: treatment options Treatment: Definitive induction chemotherapy; hydroxyurea Management of tumor lysis syndrome: intravenous fluid, allopurinol or rasburicase, electrolyte replacement, alkalinization of urine, dialysis. Avoid RBC transfusions ( cell mass); FFP, platelet transfusions PRN Leukocytapheresis: Treatment of leukocytosis/leukostasis ( surgical debulking ) May metabolic sequellae of tumor cell lysis syndrome ASFA Cat. I (leukostasis); ASFA Cat. III (prophylaxis) Indication for leukocytapheresis: - Clinical evidence of leukostasis; blast crisis; hyperleukocytosis - Blast crisis: blast cells >75% or blast cell count >100K 5
6 Acute Leukemia: Suggested Leukocytapheresis Goals Daily leukocytapheresis until patient reaches WBC goal (before initiation of definitive chemotherapy): usually 1-3 treatments: ASFA recommendations: treatment goals: - AML: asymptomatic pts: WBC <100K symptomatic pts: WBC <50K & no leukostasis sxs - ALL: asymptomatic pts: WBC <400K symptomatic pts: WBC <400K & no leukostasis sxs 6
7 Acute Leukemias: AML Acute Myelogenous Leukemia: WBC ~ K: pts present with leukostasis (CNS &/or resp.) sxs Myeloblasts: very large, stiff, non-deformable, tend to adhere to each other causing WBC thrombi at lower WBC counts. WBC 45-60% per treatment Usually 1-3 leukapheresis txs to reach WBC goal Recommend post-tx CBC (assess immediate WBC): - rarely rebound in WBC: minimal to no splenomegaly 7
8 Acute Leukemias: ALL Acute Lymphoblastic Leukemia: WBC ~ K: pts present with leukostasis (CNS &/or resp.) sxs Lymphoblasts: large, deformable, tend to adhere less to each other, only causing WBC thrombi at higher WBC counts. WBC 35-45% per treatment Usually 1-4 leukapheresis txs to reach WBC goal Recommend post-tx CBC (assess immediate WBC): - often notable rebound in WBC because of moderate splenomegaly 8
9 WBC Leukocytapheresis (WBC sequestration & rebound) 1000K Leukocytapheresis Leukocytapheresis 560K 500K Chemo Time 0 470K 380K Platelets PRBC 22:00 01:30 11:00 14:00 12 y.o. pt with ALL: WBC 780K (60% blasts), resp. distress, confusion, spleen 5 cm RCM. S. Torloni, Mayo Clinic, Scottsdale, AZ 9
10 WBC Depletion in Acute Leukemia: Evidence from the literature (1) Safety & effectiveness of leukocytapheresis in AML & ALL (~18 case series, cohort studies, or controlled trials); no RCTs: Bug et al (2007): retrospective, cohort study (53 pts with AML): - 25 pts: chemotherapy (Ch) vs. 28 pts: Ch + leukapheresis (Lp) - risk of early death (21 days): Ch + Lp group (16%) vs. Ch group (32%) - median survival similar: Ch + Lp group (7.5 mos.); Ch group (6.5 mos.) Giles et al (2001): retrospective, cohort study (146 pts with AML): - 75 pts (Ch alone) vs. 71 pts (Ch + Lp) - risk of early death (14 days): Ch + Lp group (13%) vs. Ch group (23%) - median CR similar: Ch + Lp group (62%) vs. Ch group (59%) 10
11 WBC Depletion in Acute Leukemia: Evidence from the literature (2) Chang et al (2007): retrospective, cohort study (75 pts with AML): - 37 pts (Ch) vs. 38 pts (Ch + Lp [22] or cranial irrad. [10] or both [6]) - risk of death (30 d): Ch/Lp/CI group (40%) vs. Ch group (27%) - mean survival: Ch/Lp/CI group (10.6 mos.) vs. Ch group (34.8 mos.) - WBC>200K: Ch/Lp/CI group (34%) vs. Ch group (16%) - 2 sxs of leukostasis: Ch/Lp/CI group (32%) vs. Ch group (16%) Thiebaut et al (2000): retrospective, case series (53 pts with AML): - 53 pts (Lp +/- Ch); median # txs = 1 (1-4 txs); early death (7 days): 3.8% - low level of early death 96% (51/53) pts received induction chemo. 11
12 WBC Depletion in Acute Leukemia: Evidence from the literature (3) Summary: Leukapheresis appears to decrease short-term mortality rate; does not increase overall survival. Pts selected for leukapheresis treatment are often sicker and have a higher underlying mortality rate. Leukapheresis appears to be helpful to survive blast crisis and start induction chemotherapy. Bruserud O et al. Transfus Med 2013; 23 (6): Hofmann JC et al. Blood 2011; 118 (21): abstr Bug G et al. Transfusion 2007; 47: Lowe EJ et al. Pediatr Blood Cancer 2005; 45: Chang MC et al. Am J Hematol 2007; 82 (11): Porcu P et al. Ther Apher 2002; 6: Blum W, Porcu P. Semin Thromb Hemost 2007; 33 (4): Giles FJ et al. Leuk Lymphoma 2001; 42: Novotny JR et al. Eur J Haematol 2005; 74: Thiebaut A et al. Ann Hematol 2000; 79:
13 AML & ALL patients (1/06-9/13) 1/06-9/13: 3,164 patients (pts); 24,708 apheresis treatments (txs) Acute leukemia (AML or ALL): 231 pts (7.3%); 593 txs (2.4%) - AML: 143 pts (4.5%); 320 leukocytapheresis txs - ALL: 88 pts (2.8%); 273 leukocytapheresis txs Retrospective, case series: - Blast crisis: blast cells >75% or blast cell count >100K - Leukostasis symptoms (sxs): CNS and/or pulmonary manifestations - Goals: AML pts: WBC <55K & resolution of leukostasis sxs ALL pts: WBC <80-100K & resolution of leukostasis sxs - Outcomes scale: improved; stabilized; unchanged - Improved: attain WBC goal & resolution of leukostasis sxs - Stabilized: attain >50% reduction in WBC & resolution of sxs - Unchanged: attain neither WBC level; no resolution of sxs 13
14 AML patients (ACG database: 1/06-9/13) AML (143 pts; 320 txs): Median initial WBC: 213K (range K); final WBC: 53K (17-137K) Median # txs: 2 (mean 2.2 txs/pt; range 1-5 txs); WBC 45-60% per tx Median age: 52 years old (y.o.) (6-85 y.o.); <20 y.o. (13%) Blast crisis: 89%; Leukostasis sxs: 0 sxs (11%), 1 sx (53%), 2 sxs (36%) Outcome: Improved (73%); stabilized (25%); unchanged (2%) Received induction chemotherapy: 91% pts Expired pts: 12 pts (8.4%) expired w/i 1-4 days after completing txs: - blast crisis (83%); 2 sxs leukostasis (75%); prior ICH or CVA (42%) - ventilated/hypotensive (100%); unable to tolerate chemotherapy (92%) Non-treated pts: 17 additional pts: - 11 pts: stabilized/received induction chemotherapy - 6 pts: too unstable to treat (all expired within 24 hours) 14
15 ALL patients (ACG database: 1/06-9/13) ALL (88 pts; 273 txs): Median initial WBC: 341 (range K); final WBC: 77K (30-297K) Median # txs: 2 (mean 3.1 txs/pt, range 1-7 txs); WBC 35-45% per tx Median age: 19 years old (y.o.) (3-80 y.o.); <20 y.o. (36%) Blast crisis: 84%; Leukostasis sxs: 0 sxs (21%), 1 sx (65%), 2 sxs (14%) Outcome: Improved (61%); stabilized (36%); unchanged (3%) Received induction chemotherapy: 97% pts Expired pts: 2 pt (2.3%) expired w/i 1 day after completing treatments: + blast crisis, 2 sxs leukostasis, prior ICH, ventilated/hypotensive + unable to tolerate chemotherapy Non-treated pts: 4 additional pts: - 3 pts: stabilized/received induction chemotherapy - 1 pt: too unstable to treat (expired within 24 hours) 15
16 Study Limitations Retrospective, case series (not cohort or prospective study) Lack of long-term outcome data Some ALL patients may have been overtreated 16
17 Summary: Hyperleukocytosis, leukostasis, and WBC depletion Carefully selected patients with acute leukemia (and evidence of impending thrombosis) appear to benefit significantly from WBC depletion. A limited number of treatments (median 2 treatments) can enable a high percentage of patients to receive induction chemotherapy, improves short-term clinical outcomes, and is critical to allow patients to proceed to definitive treatment. A randomized controlled trial to assess efficacy of leukocytapheresis treatment in this subset of patients (specifically patients with ALL) should be considered. 17
18 Thank you for your attention 18
19 19
20 Summary: WBC Depletion in Acute Leukemia: Evidence from the literature (3) Leukapheresis appears to decrease short-term mortality rate; does not increase overall survival. Pts selected for leukapheresis treatment are often sicker and have a higher underlying mortality rate. Leukapheresis appears to be helpful to survive blast crisis and start induction chemotherapy. Given the relatively few clinical trials in ALL (studying the utility of leukapheresis), a RCT should potentially be considered. Bruserud O et al. Transfus Med 2013; 23 (6): Hofmann JC et al. Blood 2011; 118 (21): abstr Bug G et al. Transfusion 2007; 47: Lowe EJ et al. Pediatr Blood Cancer 2005; 45: Chang MC et al. Am J Hematol 2007; 82 (11): Porcu P et al. Ther Apher 2002; 6: Blum W, Porcu P. Semin Thromb Hemost 2007; 33 (4): Giles FJ et al. Leuk Lymphoma 2001; 42: Novotny JR et al. Eur J Haematol 2005; 74: Thiebaut A et al. Ann Hematol 2000; 79:
Managing patients with bulky cancers
SIOP PODC Supportive Care Education (ICON 2016) Presentation Date: 23 rd January 2016 Recording Link at www.cure4kids.org: https://www.cure4kids.org/ums/home/conference_rooms/enter.php?room=p2pjfjp8nha
More informationTherapeutic Leukocyte Reduction (TLR) For Myeloid Leukaemia's : A Four Year Experience From An Oncology Centre In India
Therapeutic Leukocyte Reduction (TLR) For Myeloid Leukaemia's : A Four Year Experience From An Oncology Centre In India Anita Tendulkar, Jain P, Gupta A, Sharma N, Navkudkar A, Patle V Dr Anita Tendulkar
More informationHematologic Emergency. Le Wang, MD, PhD Hematology & Oncology
Hematologic Emergency Le Wang, MD, PhD Hematology & Oncology Severe Thrombocytopenia (ITP) Clinical: bleeding risk 0 no bleeding; 1 minimal bleeding after trauma; 2 spontaneous but selflimited bleeding;
More informationManagement of children with acute leukemia and an elevated white blood cell count at diagnosis hyperleukocytosis
Approved by Haem/Onc/BMT/Imm/Allergy Quality, Utilization and Patient Care Committee: May 11, 2009 Approved by Leukemia and Lymphoma Section: May 2009 1.0 Introduction: Newly diagnosed children with acute
More informationHematologic Emergencies. Udomsak Bunworasate Chulalongkorn University
Hematologic Emergencies Udomsak Bunworasate Chulalongkorn University Hematologic Emergencies Hyperleukocytosis Tumor lysis syndrome SVC syndrome Spinal cord compression Hypercalcemia 1. Hyperleukocytosis
More informationApheresis in Hematology (Erythrocytapheresis in Sickle Cell Disease) Haewon C. Kim, M.D.
Apheresis in Hematology (Erythrocytapheresis in Sickle Cell Disease) Haewon C. Kim, M.D. The Children s Hospital of Philadelphia Perelman School of Medicine University of Pennsylvania Philadelphia, PA,
More informationEasy Trick to Spot Leukemia for Pediatricians
Easy Trick to Spot Leukemia for Pediatricians Piya Rujkijyanont, MD Division of Hematology-Oncology Department of Pediatrics Phramongkutklao Hospital Most Common Pediatric Cancers Age 0-14 Leukemia 32%
More informationWhite Cell Depletion for Leukocytosis
White Cell Depletion for Leukocytosis Objectives Discuss the indication for leukoreduction Identify IV access needs for patients receiving leukapheresis Outline ways to maintain fluid and electrolyte balance
More informationCharles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162
Charles Mxxx DCEM2 Toulouse Purpan Medical School 01/26/2012 ECN Item 162 Definition Pathophysiology Clinical signs and symptoms Biology and Diagnosis Different types of AL Prognosis and Treatment Malignant
More informationThings to never miss in the office. Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC
Things to never miss in the office Brett Houston MD FRCPC (PYG-5, hematology) Leonard Minuk MD FRCPC Presenter Disclosure Faculty / Speaker s name: Brett Houston / Leonard Minuk Relationships with commercial
More information2.1 mmol/l or 25% increase from baseline mmol/l or 25% decrease from baseline
22.1 Hyperleukocytosis and tumour lysis syndrome The guideline is addressed for ALL patients with hyperleukocytosis (WBC 100 x109/l) only and should not be used without modifications in case of other diseases
More informationNorth West London Cancer Network
GUIDELINES FOR THE MANAGEMENT OF ADULT ACUTE LEUKAEMIA INITIAL MANAGEMENT CONSIDERATIONS N.B.: If AML is suspected definitively diagnosed, please ensure that the patient is transferred immediately f treatment
More informationTumor Lysis Syndrome Nephrology Grand Rounds Tuesday, July 27 th, 2010 Aditya Mattoo
Tumor Lysis Syndrome Nephrology Grand Rounds Tuesday, July 27 th, 2010 Aditya Mattoo Outline Background/Definition Epidemiology/Risk Stratification Pathophysiology Treatment Renal Replacement Therapy Background/Definition
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal tumors, in children, 530 531 Alkalinization, in tumor lysis syndrome, 516 Allopurinol, in tumor lysis syndrome, 515 Anaphylaxis, drug
More informationWhat is a hematological malignancy? Hematology and Hematologic Malignancies. Etiology of hematological malignancies. Leukemias
Hematology and Hematologic Malignancies Cancer of the formed elements of the blood What is a hematological malignancy? A hematologic malignancy is a malignancy (or cancer) of any of the formed elements
More informationApheresis Review Session Clinical Applications: Therapeutics
Apheresis Review Session Clinical Applications: Therapeutics Jeffrey L. Winters, M.D. Division of Transfusion Medicine American Society for Apheresis 2017 Annual Meeting Fort Lauderdale, Florida 2011 MFMER
More informationTherapeutic Leukapheresis in Patients with Leukostasis Secondary to Acute Myelogenous Leukemia
Journal of Clinical Apheresis 26:181 185 (2011) Therapeutic Leukapheresis in Patients with Leukostasis Secondary to Acute Myelogenous Leukemia Gil Cunha De Santis, 1 Luciana Correa Oliveira de Oliveira,
More informationGOOD MORNING! July 3, 2014
GOOD MORNING! July 3, 2014 OUR PATIENT 4yo Female with: 2 days of fever, sore throat, swollen nodes in neck and abdominal pain PMH: Tonsillectomy age 2 Immunizations: UTD NKDA DIFFERENTIAL: OUR PATIENT
More informationHaematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital
Haematological Emergencies (Part 1) Ray Mun Koo Haematology Advanced Trainee Canberra Hospital Case Number 1 43 year old male presenting with fevers, abdominal distension and weight gain over 2 weeks.
More informationM Y ELO I D D I FFER ENTIATI O N OPENS UP THE POSSIBILITIES
IDHIFA (enasidenib) is indicated for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with an isocitrate dehydrogenase-2 (IDH2) mutation as detected by an
More informationFocus on aggressive polycythemia vera
Focus on aggressive polycythemia vera Jerry L. Spivak, MD Professor of Medicine and Oncology Director, the Johns Hopkins Center for the Chronic Myeloproliferative Disorders Johns Hopkins University School
More informationThrombotic Thrombocytopenic
The Treatment of TTP and the Prevention of Relapses GERALD APPEL, MD Professor of Clinical Medicine Columbia University College of Physicians and Surgeons NY-Presbyterian Hospital New York, New York Thrombotic
More informationNicole Laferriere MD PhD FRCPC April 10, Patient Case Studies: Sticky Situations For Platelet Transfusions
Nicole Laferriere MD PhD FRCPC April 10, 2019 Patient Case Studies: Sticky Situations For Platelet Transfusions Disclosures Ad Board: Celgene, Jansen, Takeda, Roche, Sanofi, Leo, Shire, Servier, Phizer,
More informationAssessing thrombocytopenia in the intensive care unit: The past, present, and future
Assessing thrombocytopenia in the intensive care unit: The past, present, and future Ryan Zarychanski MD MSc FRCPC Sections of Critical Care and of Hematology, University of Manitoba Disclosures FINANCIAL
More informationThrombocytosis. Leukemias Cell Therapies
Clinical Applications of Therapeutic Apheresis Presentation: Prof. A. Pourazar TA Technologies Membrane Prisma Gambro BCT Asahi Plasma Flow Centrifugation Cascade apheresis for selective plasma component
More informationMedical Surgical Review Handout- Hematology/Oncology 2016
Medical Surgical Review Handout- Hematology/Oncology 2016 Overview Blood circulates in the cardiovascular system o Carries oxygen to the cells o Carries waste away from the cells Functions of blood o Transportation:
More informationMS.4/ Acute Leukemia: AML. Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD
MS.4/ 27.02.2019 Acute Leukemia: AML Abdallah Al Abbadi.MD.FRCP.FRCPath Feras Fararjeh MD Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising
More informationFunding for this publication for Joshua A Levine is from Northwestern University, Department of Medicine, Physician Scientist Training Program Grant
AACE Clinical Case Reports Rapid Electronic Articles in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited,
More informationHyperleucocytosis in acute and chronic leukaemias (Myeloid & lymphoid Types)
Biohealth Science Bulletin 2011, 3(1), 20-28 Hussein U Y et al. 2011 Hussein U Y*, Yusoff N M Transfusion Medicine Cluster, Advanced Medical & Dental Institute (AMDI),Universiti Sains Malaysia (USM). (Received
More informationMS.4/ 1.Nov/2015. Acute Leukemia: AML. Abdallah Abbadi
MS.4/ 1.Nov/2015. Acute Leukemia: AML Abdallah Abbadi Case 9: Acute Leukemia 29 yr old lady complains of fever and painful gums for 1 week. She developed easy bruising and hemorrhagic spots on her trunk
More informationOncologic Emergencies. Angelina The, MD Lynn Cancer Institute August 30, 2016
Oncologic Emergencies { Angelina The, MD Lynn Cancer Institute August 30, 2016 What constitutes an oncologic emergency? Complications arising from Cancer Paraneoplastic syndrome Treatment of cancer Requires
More informationTherapeutic Apheresis in South America
Therapeutic Apheresis in South America Alfredo Mendrone Jr, MD, PhD Fundação Pró-Sangue Hemocentro de SP / University of São Paulo São Paulo - Brazil Therapeutic Apheresis in Brazil The beginning... Late
More informationDiagnosis / Lab Findings
Diagnosis / Lab Findings During at acute episode may see Peripheral smear bite cells, Heinz bodies Reticulocytosis Increased indirect bilirubin G6PD will be normal or high during an acute crisis Repeat
More informationHematological Emergencies: What every Hospitalist needs to know
Hematological Emergencies: What every Hospitalist needs to know C. Tom Kouroukis MD MSc FRCPC Juravinski Hospital and Cancer Centre Division of Malignant Hematology Department of Oncology McMaster University
More informationDisclosures/COI. Cases in Hematopathology. Outline. Heme Path Findings Not to Miss. Normal Peripheral Smear 6/30/2016
Disclosures/COI Cases in Hematopathology Vamsi Kota Assistant Professor Department of Hematology & Medical Oncology Leukemia/BMT I have no disclosures or conflicts of interest regarding this presentation.
More informationDivision of General Internal Medicine and Geriatrics Hospital Medicine 2014
Division of General Internal Medicine and Geriatrics Hospital Medicine 2014 Objectives Understand workup of acute pain crisis Identify key aspects of management of acute pain crisis in sickle cell patients
More informationTherapeutic Apheresis. SEABB Courtney Hopkins, D.O. American Red Cross, Southern Region
Therapeutic Apheresis SEABB Courtney Hopkins, D.O. American Red Cross, Southern Region Outline Indication Categories Clinical Indications (I and II) Extracorporeal Photopheresis American Red Cross Therapeutic
More informationBeyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura
Beyond Plasma Exchange: Targeted Therapy for Thrombotic Thrombocytopenic Purpura Kristen Knoph, PharmD, BCPS PGY2 Pharmacotherapy Resident Pharmacy Grand Rounds April 25, 2017 2016 MFMER slide-1 Objectives
More informationCase-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT
Case-Control Study: ABO-Incompatible Plasma Causing Hepatic Veno-Occlusive Disease in HSCT Erin Meyer, DO, MPH Assistant Medical Director of Blood, Tissue, and Apheresis Services Children s Healthcare
More informationIndex. Note: Page numbers of article titles are in boldface type.
Note: Page numbers of article titles are in boldface type. A Abdominal radiotherapy, toxic effects of, 636 637 Acute promyelocytic leukemia, associated with acquired bleeding problems, 614 615 Acute renal
More informationIndex. Note: Page numbers of article titles are in boldface type.
Index Note: Page numbers of article titles are in boldface type. A Abdomen, acute, in oncological surgery patients, critical care issues in, 101 102 Acquired factor VIII inhibitors, in critically ill cancer
More informationProphylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010
Prophylactic Cranial Irradiation in Acute Lymphoblastic Leukemia: Is there still an indication? Celine Bicquart, MD Radiation Medicine May 5, 2010 Outline Epidemiology Risk-groups Background & Rationale
More informationLeukocyte Depletion by Therapeutic Leukocytapheresis in Patients with Leukemia
Review Article Übersichtsarbeit Transfus Med Hemother 2012;39:241 245 DOI: 10.1159/000341805 Received: March 20, 2012 Accepted: July 12, 2012 Published online: July 26, 2012 Leukocyte Depletion by Therapeutic
More informationMyeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas. James J. Stark, MD, FACP
Myeloproliferative Disorders: Diagnostic Enigmas, Therapeutic Dilemmas James J. Stark, MD, FACP Medical Director, Cancer Program and Palliative Care Maryview Medical Center Professor of Medicine, EVMS
More informationMYELODYSPLASTIC AND MYELOPROLIFERATIVE
MYELODYSPLASTIC AND MYELOPROLIFERATIVE DISORDERS Pediatric Hemato-Oncology Division Medical Faculty University of Sumatera Utara 1 MYELODYSPLASIA SYNDROME A group of disorder defect in hematopoetic cell
More informationDonor Lymphocyte Infusion for Malignancies Treated with an Allogeneic Hematopoietic Stem-Cell Transplant
Last Review Status/Date: September 2014 Page: 1 of 8 Malignancies Treated with an Allogeneic Description Donor lymphocyte infusion (DLI), also called donor leukocyte or buffy-coat infusion is a type of
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationLymphocyte Predominant Hodgkin s Lymphoma. Case Presentation. How would you treat the patient?
Lymphocyte Predominant Hodgkin s Lymphoma Wei Ai, MD, PhD Assistant Clinical Professor University of California, San Francisco January 2010 Case Presentation 32 yo male, diagnosed with stage IIIA lymphocyte
More informationHighest rates of thrombosis = age > 70, history of thrombosis, active disease (> 6 phlebotomies/yr) [2]
Polycythemia Vera Treatment Policy Prepared by Dr. Jeannie Callum Updated May 2003 Introduction PV is a chronic, clonal, myeloproliferative disorder, classically associated with an increase in red cell
More informationRisk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities
Risk Evaluation and Mitigation Strategy (REMS): Cytokine release syndrome and neurological toxicities A REMS is a program required by the FDA to manage known or potential serious risks associated with
More informationAn Approach to the Patient Refractory to Platelets Transfusion. Harold Alvarez, MD
Harold Alvarez, MD Objectives Explain the etiology of platelet refractoriness Discuss the different types of platelet refractoriness Describe how platelet refractoriness is diagnosed Discuss different
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationIf unqualified, Complete remission is considered to be Haematological complete remission
Scroll right to see the database codes for Disease status and Response Diagnosis it refers to Disease status or response to treatment AML ALL CML CLL MDS or MD/MPN or acute leukaemia secondary to previous
More informationA PRIMER ON APHERESIS MEDICINE
A PRIMER ON APHERESIS MEDICINE Nicole Aqui, M.D. Assistant Professor Division of Transfusion Medicine Department of Pathology and Laboratory Medicine University of Pennsylvania What is Apheresis? Apheresis
More informationCrackCast Episode 7 Blood and Blood Components
CrackCast Episode 7 Blood and Blood Components Episode Overview: 1) Describe the 3 categories of blood antigens 2) Who is the universal donor and why? 3) Define massive transfusion 4) List 5 physiologic
More informationCAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes. Shannon L.
CAR T-Cell Therapy for Acute Lymphoblastic Leukemia: Identifying Appropriate Patients and Maximizing Outcomes Shannon L. Maude, MD, PhD CTL019 cell Lentiviral vector Anti-CD19 CAR construct CD19 Native
More informationApheresis: Clinical Indications
PART 2 Apheresis: Clinical Indications Clinical Vignettes: Hematology Cardiology/Vascular Neurology Solid Organ Transplantation Anatomy of an ASFA Fact Sheet Hematology 40 yo M presenting to the Emergency
More informationSTEM CELL TRANSPLANT IN PEDIATRICS. Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17
STEM CELL TRANSPLANT IN PEDIATRICS Erin Meyer, DO, MPH Medical Director, Apheresis Nationwide Children s Hospital Columbus, OH 5/6/17 Disclosures Nothing to Disclose Overview Stem Cell Transplant History
More informationHEMATOLOGIC & ONCOLOGIC EMERGENCIES MEG KELLEY MS, FNP- BC, OCN
HEMATOLOGIC & ONCOLOGIC EMERGENCIES MEG KELLEY MS, FNP- BC, OCN COURSE OBJECTIVES At the conclusion of this presentation, participants should be able to: 1. Define hematological and oncologic (heme-onc)
More informationULYRICE. Protocol Code. Lymphoma. Tumour Group. Dr. Laurie Sehn. Contact Physician
BCCA Protocol Summary for the Treatment of Relapsed or Refractory Advanced Stage Aggressive B-Cell Non-Hodgkin s Lymphoma with Ifosfamide, CARBOplatin, Etoposide and rituximab Protocol Code Tumour Group
More informationJeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ
Jeanne Palmer February 26, 2017 Mayo Clinic, Phoenix, AZ What is acute leukemia? Cancer of the white blood cells Acute leukemia- Acute myelogenous leukemia Acute myeloid leukemia Myelofibrosis- Blast phase
More informationKylie Lepic BSc, MD, FRCPC CAGPO Conference
Acute Leukemia Kylie Lepic BSc, MD, FRCPC CAGPO Conference Oct 19, 2013 1 Disclosures No conflicts of interest 2 Objectives Case presentation Classification of leukemia Clinical manifestations Diagnosis
More informationObjectives. I do not have anything to disclose.
Treatment of APL Objectives I do not have anything to disclose. Objectives 1. Urgency of early recognition and treatment 2. Treatment based on risk stratification 3. Monitoring for relapse 4. Treatment
More informationRecommended Timing for Transplant Consultation
REFERRAL GUIDELINES Recommended Timing for Transplant Consultation Published jointly by the National Marrow Donor Program /Be The Match and the American Society for Blood and Marrow Transplantation BeTheMatchClinical.org
More informationSWOG ONCOLOGY RESEARCH PROFESSIONAL (ORP) MANUAL LEUKEMIA FORMS CHAPTER 16A REVISED: DECEMBER 2017
LEUKEMIA FORMS The guidelines and figures below are specific to Leukemia studies. The information in this manual does NOT represent a complete set of required forms for any leukemia study. Please refer
More informationGUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS
CHILDREN S HOSPITALS AND CLINICS OF MINNESOTA Introduction: GUIDELINES FOR THE TRANSFUSION OF BLOOD COMPONENTS These guidelines have been developed in conjunction with the hospital Transfusion Committee.
More informationCase Workshop of Society for Hematopathology and European Association for Haematopathology
Case 148 2007 Workshop of Society for Hematopathology and European Association for Haematopathology Robert P Hasserjian Department of Pathology Massachusetts General Hospital Boston, MA Clinical history
More informationLifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA Transfusion Criteria Version#2 POLICY NO.
LifeBridge Health Transfusion Service Sinai Hospital of Baltimore Northwest Hospital Center BQA 1011.02 Transfusion Criteria Version#2 Department POLICY NO. PAGE NO. Blood Bank Quality Assurance Manual
More informationSingle-Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults
Single-Dose Rasburicase 6 mg in the Management of Tumor Lysis Syndrome in Adults Anne M. McDonnell, Pharm.D., Kristi L. Lenz, Pharm.D., Debra A. Frei-Lahr, M.D., John Hayslip, M.D., and Philip D. Hall,
More informationThrombotic Microangiopathies
Thrombotic Microangiopathies ASH/San Antonio Breast Cancer Symposium Review James N. George March 14, 2015 Thrombotic Microangiopathies (TMA): Everything you need to know from 5 patient stories Thrombotic
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: September 15, 2016 Gazyva Description Gazyva (obinutuzumab)
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Subject: Granix 1 of 7 Last Review Date: September 18, 2015 Granix Description Granix (tbo-filgrastim)
More informationLeukemias. Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College
Leukemias Prof. Mutti Ullah Khan Head of Department Medical Unit-II Holy Family Hospital Rawalpindi Medical College Introduction Leukaemias are malignant disorders of the haematopoietic stem cell compartment,
More informationMost Common Hemostasis Consults: Thrombocytopenia
Most Common Hemostasis Consults: Thrombocytopenia Cindy Neunert, MS MSCS Assistant Professor, Pediatrics CUMC Columbia University TSHNA Meeting, April 15, 2016 Financial Disclosures No relevant financial
More informationBlood Transfusion Guidelines in Clinical Practice
Blood Transfusion Guidelines in Clinical Practice Salwa Hindawi Director of Blood Transfusion Services Associate Professor in Haematology and Transfusion Medicine King Abdalaziz University, Jeddah Saudi
More informationGuideline for platelet transfusion thresholds for pediatric hematology/oncology patients. Khoa Ung bướu - Huyết học
Guideline for platelet transfusion thresholds for pediatric hematology/oncology patients Khoa Ung bướu - Huyết học Reference Sources: C17 Council (Canada) Guideline release date: June, 2010; Literature
More informationSpontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer
Open Access Case Report DOI: 10.7759/cureus.1017 Spontaneous Tumor Lysis Syndrome in Small Cell Lung Cancer Venkatkiran Kanchustambham 1, Swetha Saladi 2, Setu Patolia 2, David Stoeckel 2 1. Pulmonary
More informationTransfusion Indications: Update in 2019
Transfusion Indications: Update in 2019 Yulia Lin, MD, FRCPC, CTBS Division Head, Transfusion Medicine, Sunnybrook HSC Associate Professor, Dept of Laboratory Medicine and Pathobiology, University of Toronto
More informationLEUKAEMIA and LYMPHOMA. Dr Mubarak Abdelrahman Assistant Professor Jazan University
LEUKAEMIA and LYMPHOMA Dr Mubarak Abdelrahman Assistant Professor Jazan University OBJECTIVES Identify etiology and epidemiology for leukemia and lymphoma. Discuss common types of leukemia. Distinguish
More informationHematology 101. Rachid Baz, M.D. 5/16/2014
Hematology 101 Rachid Baz, M.D. 5/16/2014 Florida 101 Epidemiology Estimated prevalence 8,000 individuals in U.S (compare with 80,000 MM patients) Annual age adjusted incidence 3-8/million-year 1 More
More informationThrombohemorrhagic disorders in APL: the unsolved issue
Thrombohemorrhagic disorders in APL: the unsolved issue Pau Montesinos Hospital La Fe. Valencia, Spain 7th International Symposium on Acute Promyelocytic Leukemia Rome, Italy (September 2017) Background
More informationJo Abraham MD Division of Nephrology University of Utah
Jo Abraham MD Division of Nephrology University of Utah 68 year old male presented 3 weeks ago with a 3 month history of increasing fatigue He reported a 1 week history of increasing dyspnea with a productive
More informationHyperleucocytic chronic myeloid leukemia with facial nerve palsy at presentation
www.edoriumjournals.com CASE REPORT PEER REVIEWED OPEN ACCESS Hyperleucocytic chronic myeloid leukemia with facial nerve palsy at presentation Adama Isah Ladu, Aisha Mohammed Abba ABSTRACT Introduction:
More informationPCCN Review Hematology
PCCN Review Hematology Leanna R. Miller, RN, MN, CCRN-CMC, PCCN-CSC CEN, CNRN, CMSRN, NP Education Specialist LRM Consulting Nashville, TN Anemia Definition reduction in RBC concentration Causes iron deficiency
More informationAnand P. Jillella, MD; FACP Professor, Hematology and Medical Oncology Associate Director for Community Affairs and Outreach Winship Cancer Institute
Anand P. Jillella, MD; FACP Professor, Hematology and Medical Oncology Associate Director for Community Affairs and Outreach Winship Cancer Institute of Emory University Atlanta, GA 1 Multiple Choice #1
More informationDIC. Disseminated intravascular coagulation, is a life threatening pathological process in which clotting factors are abnormally activated.
Miss. kamlah 1 DIC Disseminated intravascular coagulation, is a life threatening pathological process in which clotting factors are abnormally activated. Resulting in wide spread of clot formation in the
More informationMyelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data
Instructions for Myelodysplasia/Myeloproliferative Neoplasms (MDS/MPN) Post-HCT Data (Form 2114) This section of the CIBMTR Forms Instruction Manual is intended to be a resource for completing the Myelodysplasia/Myeloproliferative
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.85.16 Subject: Granix 1 of 7 Last Review Date: December 2, 2016 Granix Description Granix (tbo-filgrastim)
More informationEducational Session: Oncology Emergencies
Educational Session: Oncology Emergencies Diane M. Birnbaumer, MD, FACEP 3/24/2010 10:00 AM - 11:00 AM Oncologic Emergencies Diane M. Birnbaumer, M.D., FACEP Professor of Medicine University of California,
More informationThe Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011)
The Power of Peripheral Blood Smears: Apparent Diagnostic Clues (Part 1) (Wednesday, October 19, 2011) By Gene Gulati, Ph.D., SH(ASCP) Conflict of Interest None Plan for the Course Review blood smears,
More informationDigital Washington University School of Medicine. Russell Schilder Fox Chase Comprehensive Cancer Center. Arturo Molina Biogen Idec
Washington University School of Medicine Digital Commons@Becker Open Access Publications 2004 Follow-up results of a phase II study of ibritumomab tiuetan radioimmunotherapy in patients with relapsed or
More informationGranix. Granix (tbo-filgrastim) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.16 Section: Prescription Drugs Effective Date: April 1, 2014 Subject: Granix 1 of 7 Last Review Date:
More informationSafety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Dialysis
SP281 Safety and Efficacy of Eculizumab in Pediatric Patients With ahus, With or Without Baseline Johan Vande Walle, 1 Larry A. Greenbaum, 2 Camille L. Bedrosian, 3 Masayo Ogawa, 3 John F. Kincaid, 3 Chantal
More informationGazyva. Gazyva (obinutuzumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.29 Subject: Gazyva Page: 1 of 7 Last Review Date: March 16, 2018 Gazyva Description Gazyva (obinutuzumab)
More informationAcute leukemia. Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation
Acute leukemia Ibrahim Aldoss, MD Assistant Professor, City of Hope Hematology and Hematopoietic Cell Transplantation Helocyte- Advisory board Acute myeloid leukemia (AML) Heterogeneous clonal malignancy
More informationThis was a multicenter study conducted at 11 sites in the United States and 11 sites in Europe.
Protocol CAM211: A Phase II Study of Campath-1H (CAMPATH ) in Patients with B- Cell Chronic Lymphocytic Leukemia who have Received an Alkylating Agent and Failed Fludarabine Therapy These results are supplied
More informationHow hematologists perceive critical care- Acute myeloid leukemia
How hematologists perceive critical care- Acute myeloid leukemia Groupe de Recherche Respiratoire en Réanimation Onco-Hématologique Research Meeting June 30 th 2011 Peter Schellongowski Intensive Care
More informationFlow Cytometry. Leukemia and Myelodysplastic Syndromes. Bone Marrow Aspirate and Biopsy
Diagnostic Evaluation of Blood Disorders Leukemia and Myelodysplastic Syndromes Lenise Taylor, MN, RN, AOCNS, BMTCN BMT/Immunotherapy CNS Seattle Cancer Care Alliance/UWMC ltaylor@seattlecca.org History
More information